Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML

FOSTER CITY, Calif.--(BUSINESS WIRE) August 21, 2023 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in U.S. studies...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials